Top Injectable Manufacturer in Saudi Arabia – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 5 days ago
- 11 min read
Last Updated: July 20, 2026
TL;DR: Saudi Arabia — a market of roughly 35 million people, more than 40% of them expatriates, accounting for around 60% of GCC healthcare expenditure and pharmaceutical purchasing — is regulated by one of the most capable authorities in the region. The Saudi Food and Drug Authority reached WHO Global Benchmarking Tool Maturity Level 4 in October 2023, the first in the Eastern Mediterranean Region and third worldwide to do so. Marketing authorisation is filed in eCTD format with a Saudi-specific Module 1 through the Saudi Drug Registration (SDR) system, runs five years, requires a locally licensed authorised representative, and is followed by a separate SFDA pricing step based on external reference pricing. Stability must be generated at 30°C/65% RH, the GCC-harmonised long-term condition — not the temperate 25°C/60% RH that is often wrongly assumed. Serialisation under SFDA's RSD track-and-trace system is mandatory for all products entering the supply chain. Farbe Firma Pvt Ltd is a WHO-GMP certified injectable manufacturer and CDMO in Gujarat, India, producing more than 100 sterile injectables under ISO Class 5 aseptic conditions and exporting to 30+ countries, with CTD/eCTD dossier capability, GS1-compliant serialisation, Certificates of Pharmaceutical Product and stability data that already exceeds the Saudi humidity requirement.
Key Takeaways
A high-capability regulator and a precise pathway: the SFDA holds WHO Maturity Level 4, awarded in October 2023 — the highest tier under the WHO Global Benchmarking Tool. Marketing authorisation is submitted in eCTD format with a Saudi-specific Module 1 through the Saudi Drug Registration (SDR) system, is valid for five years, and requires a locally licensed Saudi authorised representative appointed by the manufacturer. Registration is followed by a separate SFDA pricing decision made on an external reference pricing basis, so pricing strategy has to be part of the filing plan rather than an afterthought.
Stability at 30°C/65% RH — the detail most suppliers get wrong: Saudi Arabia and the wider GCC have harmonised on 30°C and 65% relative humidity as the long-term stability condition, confirmed in WHO's table of stability conditions by member state. It is not 25°C/60% RH. Because Indian stability programmes are typically run at 30°C/70–75% RH, a properly built Indian package is more stringent on humidity than Saudi Arabia requires and transfers cleanly across all six GCC states.
Certified manufacturing and GMP evidence: a WHO-GMP certified plant with an ISO Class 5 aseptic core, validated water-for-injection loops, terminal moist-heat sterilisation wherever the formulation permits and validated aseptic filling where it does not, supported by environmental monitoring, media fills, container-closure integrity testing and LAL endotoxin testing on every campaign. SFDA inspects foreign manufacturing sites as part of registration, with on-site inspection sometimes waived where a site already holds GCC-DR, US FDA or EMA approval — so a WHO-GMP site should plan for an SFDA inspection and maintain continuous audit readiness.
Serialisation, Arabic labelling and market access: SFDA's RSD track-and-trace system covers all human pharmaceutical products manufactured in or imported into the Kingdom, using GS1-standard 2D barcodes carrying GTIN, batch number, expiry date and a unique serial number. Package inserts and labelling must be provided in Arabic alongside English. Government procurement is centralised through NUPCO, which requires supplier prequalification in addition to SFDA product registration, and local-content price preferences apply in government tenders — so the realistic near-term routes for an importer are the private hospital sector, distributors and products without a local equivalent.
Introduction: Why an Injectable Manufacturer in Saudi Arabia Must Meet Global Standards
Saudi Arabia is the largest healthcare market in the Gulf by a wide margin, accounting for roughly 60% of GCC healthcare expenditure and around 60% of the region's pharmaceutical purchasing. Care is delivered through a large Ministry of Health hospital network — the ministry operates the majority of the Kingdom's hospitals — alongside other government sectors and a fast-growing private sector of roughly 150 hospitals concentrated in Riyadh, Jeddah and the Eastern Province. Private provision is expanding quickly: private clinics accounted for 47% of inpatient visits in recent reporting, up from 34% in 2015, driven substantially by mandatory cooperative health insurance for expatriate workers and private-sector employees. Sterile injectables underpin the clinical work at every level of that system. Surgical anaesthesia, critical care, oncology infusion, injectable antibiotics, cardiovascular emergency medicine, dialysis support and obstetric care all depend on injectable products being present, sterile, correctly labelled and in date — and the annual Hajj and Umrah pilgrimages add a concentrated seasonal load on emergency and inpatient services that has to be planned for rather than absorbed.
The clinical demand behind that is substantial and growing. Saudi Arabia is among the ten countries with the highest diabetes prevalence worldwide: the International Diabetes Federation records 5.3 million adults living with diabetes in 2024, an age-standardised prevalence of 23.1%, with 43.6% of cases undiagnosed and a projection of 9.5 million adults by 2050. Non-communicable diseases account for around 68% of all deaths, obesity affects more than 40% of adults, and cancer and cardiovascular care are expanding accordingly. At the same time the Kingdom imports the clear majority of the medicines it uses — domestic manufacturing covers roughly a quarter to a third of demand, with around 40 registered pharmaceutical factories supplying an estimated 36% of the market's needs. That gap is the opportunity, but it is a regulated one. The SFDA reached WHO Maturity Level 4 in October 2023 and assesses dossiers and manufacturing sites to a correspondingly high standard, so an injectable supplier entering Saudi Arabia is entering a market where technical quality, documentation discipline and serialisation compliance decide access far more than price does.
What Sets a World-Class Injectable Manufacturer in Saudi Arabia Apart
The first differentiator is genuine sterile-manufacturing capability. Injectables are made in classified cleanrooms with an ISO Class 5 critical zone fed by validated water-for-injection loops and pure-steam systems, with gowning qualification, personnel flow and material airlocks designed so the aseptic core is never compromised. Heat-stable formulations are terminally sterilised by moist heat because that gives the highest and most defensible sterility assurance level; heat-labile molecules move to validated aseptic processing, proven repeatedly through media fills. Layered on top are continuous environmental monitoring, container-closure integrity testing, bacterial endotoxin testing by LAL, compendial sterility testing, HPLC and GC methods for assay and related substances, and Karl Fischer moisture determination for lyophilised presentations. The SFDA inspects foreign manufacturing sites as part of the registration process, and while on-site inspection can be waived where a site already holds GCC-DR, US FDA or EMA approval, a manufacturer relying on WHO-GMP alone should plan on being inspected — and should be able to withstand it on any given day rather than after three months of preparation.
The second differentiator is market-access support shaped around the Saudi pathway, including its two commonly underestimated steps. A foreign manufacturer cannot deal with the SFDA directly: a locally licensed Saudi authorised representative must be appointed to submit the dossier, receive correspondence and represent the manufacturer, and the company and facility are registered with the SFDA before product registration is submitted. The dossier itself is filed in eCTD format with a Saudi-specific Module 1 through the Saudi Drug Registration system, and marketing authorisation runs for five years with renewal filed ahead of expiry. The step that catches suppliers out is pricing: the SFDA sets and approves medicine prices using external reference pricing against a defined basket of countries, with price certificates revisited on the same cycle, and a lower price found in the basket can pull the Saudi price down. The other is serialisation, which is not optional and not a future requirement. Anyone treating registration as the finish line rather than the midpoint will find the launch stalls after approval.
Quality Systems Behind Every Batch We Ship to Saudi Arabia
Every Farbe Firma injectable batch destined for Saudi Arabia is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by validated HPLC and GC methods; residual solvents are controlled to ICH limits; water content in lyophilised and powder-filled presentations is measured by Karl Fischer titration; bacterial endotoxins are quantified by LAL; sterility is confirmed by the compendial method; and particulate matter, pH, fill volume, closure integrity and visual inspection are recorded against pre-set acceptance criteria. Specifications are written to USP, BP, IP or EP as the registration requires, and the certificate of analysis issued with each consignment reports measured results rather than a generic conformity statement — so an authorised representative, a NUPCO quality reviewer or a hospital pharmacist can read the data rather than trust a claim.
Behind release testing sits the quality architecture that makes those results defensible to a Maturity Level 4 regulator. Water-for-injection generation and distribution is validated and continuously monitored; sterilisation and depyrogenation cycles are qualified against biological and chemical indicators; cleaning validation demonstrates negligible carry-over at changeover; and stability is generated to ICH Q1A with ICH Q1B photostability. For Saudi Arabia and the wider Gulf the long-term condition is 30°C and 65% relative humidity, harmonised across all six GCC states, so a single stability package supports the whole region — and because Indian stability programmes are typically run at 30°C/70–75% RH, our data is more stringent on humidity than the Saudi requirement rather than needing to be regenerated. Change control, deviation management, out-of-specification investigation and annual product quality review run under a quality management system built for inspection, with electronic records under data-integrity controls and complete audit trails, so an SFDA site inspection meets a plant in its normal operating state.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Saudi Arabia for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries across the Middle East, Asia, Africa, the CIS and Latin America. The portfolio aligns closely with Saudi clinical demand: injectable antibiotics, anaesthetics and analgesics, cardiovascular and emergency medicines, oncology support, corticosteroids, antiemetics, insulin-adjacent and metabolic support products, vitamins and electrolytes, and small-volume and large-volume parenterals in ampoules, vials, lyophilised and prefilled presentations. Antibiotics and treatments for cancer, cardiovascular disease and diabetes are consistently identified as the strongest prospects in the Saudi market, which maps directly onto both our portfolio and the Kingdom's disease burden — a diabetes population of 5.3 million adults and NCDs driving around 68% of deaths generate exactly the sustained, high-volume injectable demand that rewards a stable, audited supply relationship over opportunistic sourcing.
Our CDMO services scale from a single distributor's launch portfolio to full institutional volumes, and Saudi artwork and serialisation requirements are handled as part of the build rather than as a late correction. Package inserts and labelling are prepared in Arabic alongside English, with primary packaging carrying product name, strength, batch number and manufacturing and expiry dates, and secondary packaging carrying the fuller information set. Serialisation is built to SFDA's RSD track-and-trace system, which has covered all human pharmaceutical products manufactured in or imported into the Kingdom since it came into use at the start of 2019: each saleable unit carries a GS1-standard 2D barcode encoding GTIN, batch number, expiry date and a unique serial number, with data reported into the RSD platform. Getting this right at the manufacturing site — rather than attempting to retrofit it at an importer's warehouse — is one of the practical reasons partners consolidate volume with us. Because Farbe Firma is a manufacturer rather than a trading intermediary, a Saudi partner deals directly with the organisation that owns the process: the same people answer the regulatory question, schedule the campaign, release the batch and stand behind the certificate of analysis.
Buyers stay with Farbe Firma because we are candid about how the Saudi market actually works. Government procurement is centralised through NUPCO, and only prequalified companies are invited to bid — which means registering the company with NUPCO in addition to registering products with the SFDA, and being ready to move when tenders open, because tender windows are often short. We also say plainly that Saudi procurement policy actively favours local production: national products receive a price preference in government tenders, with a further preference where a domestically produced API is used, and localising pharmaceutical manufacturing is an explicit Vision 2030 objective pursued through the National Industrial Development and Logistics Program. The realistic near-term routes for an imported injectable are therefore the private hospital sector, established importers and distributors, and products where no local equivalent exists — and we would rather help a partner target those accurately than promise tender outcomes we cannot underwrite. On logistics, consignments route through Jeddah Islamic Port, King Abdullah Port or King Abdulaziz Port in Dammam for sea freight and through the major airports for temperature-sensitive air freight, with packaging and cold-chain specified for summer ambient temperatures that routinely exceed 45°C and a documented temperature record from dispatch to delivery.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Saudi Arabia?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable products under ISO Class 5 aseptic conditions and exporting to over 30 countries. We provide the GMP certificate, Certificate of Pharmaceutical Product, site master file and batch documentation that a Saudi authorised representative needs to register products with the SFDA. The SFDA inspects foreign manufacturing sites as part of registration — an on-site inspection may be waived where a site already holds GCC-DR, US FDA or EMA approval — so we maintain the plant in continuous audit-ready condition on the assumption that we will be inspected.
How does Farbe Firma support SFDA product registration in Saudi Arabia?
We supply complete CTD and eCTD dossier modules, drug master files, ICH Q1A stability data with ICH Q1B photostability, analytical method validation and process validation reports, formatted for the Saudi Drug Registration system with its Saudi-specific Module 1. A foreign manufacturer must appoint a locally licensed Saudi authorised representative to file and to correspond with the SFDA, and we work alongside that partner through evaluation questions, site inspection and the separate SFDA pricing step, which is decided on an external reference pricing basis. Marketing authorisation runs five years, and we plan renewal ahead of expiry.
What stability conditions does Saudi Arabia require for imported injectables?
The long-term stability condition confirmed for Saudi Arabia is 30°C and 65% relative humidity, harmonised across all six GCC member states, with ICH Q1B photostability alongside it. This is frequently misstated as the temperate 25°C/60% RH condition, which would not be acceptable. Because our stability programmes are run at Indian conditions of 30°C/70–75% RH, our packages are more demanding on humidity than the Saudi requirement and transfer cleanly to Saudi Arabia and the wider Gulf without regeneration — which removes one of the most common causes of delay in a GCC filing.
Does Farbe Firma support Saudi serialisation and Arabic labelling requirements?
Yes. SFDA's RSD track-and-trace system covers all human pharmaceutical products manufactured in or imported into Saudi Arabia, and each saleable unit must carry a GS1-standard 2D barcode encoding the GTIN, batch number, expiry date and a unique serial number, with data reported into the RSD platform. We apply serialisation at the manufacturing site rather than leaving it to be retrofitted downstream. Package inserts and labelling are prepared in Arabic alongside English, with the required content on both primary and secondary packaging, and artwork is reviewed with the authorised representative before the first commercial campaign.
Can Farbe Firma supply injectables for Saudi government hospital tenders through NUPCO?
We support partners bidding into NUPCO, and we are straightforward about what that requires. Only prequalified companies are invited to submit bids, so a supplier must register the company with NUPCO as well as registering its products with the SFDA, and tender windows are often short. It is also fair to note that Saudi procurement applies price preferences to national products, with an additional preference where a domestically produced API is used, so imported products compete on an intentionally uneven field in government tenders. For most new entrants the private hospital sector, importers and distributors, and products with no local equivalent are the more realistic first routes, and we help partners plan accordingly.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments